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Abstract
Background: Over the last several years significant rises in the use of implanted cardioverter-defibril-
lators (ICD) have also resulted in a number of associated complications. This number includes lead 
failure. Sprint Fidelis (SF) ICD lead is regarded as a lead with elevated failure risk. Every center acting 
in accordance with the guidelines should observe patients more thoroughly especially with recalled leads 
and run a registry of their follow-up. The aim of this research was to present follow-up of the patients 
with SF leads (types 6948, 6949) from a single implantation center.
Methods: There were 36 SF leads implanted in 36 patients. Mean follow-up period was 76 months 
(IQR 40.3–86.8). Patients were subjected to regular check-ups in 3 to 6 month intervals.
Results: Patients were implanted at a median age of 66.5 years and majority of them had ischemic car-
diomyopathy (72%). A majority of the studied population were men (72.2%). Predominantly dual-cham-
ber ICD (ICD-DR) were implanted (50% ICD-DR vs. 47.2% ICD-VR). The guidelines for management 
of patients implanted with SF were fully implemented. During the follow-up 14 (38.9%) patients died. 
No deaths were noted that could be attributed to lead failure. In 5 cases lead failure was identified and 
of these 4 leads were replaced. Median time from implantation to the detection of lead dysfunction was  
52 months (IQR 49; 83). The symptoms of failure consisted of: inappropriate shocks, alternating ven-
tricular lead signal, or loss of ventricular stimulation.
Conclusions: The follow-up of patients with recalled SF leads in a single center supports that imple-
mentation SF management guidelines could be effective in clinical practice. (Cardiol J 2017; 24, 3: 
259–265)
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Introduction
The Sprint Fidelis (SF) 6948 and 6949 models 
(Medtronic, Minneapolis, Minnesota, USA) are 
6.6-French defibrillation leads with bipolar coil, 
coated with silicone, including a polyurethane 
overlay and of passive (6948; tines) or active (6949; 
active screw-in) fixation. This lead family has been 
in distribution since 2004. The first signals of el-
evated risk of fracture emerged in July 2007 when 
Hauser et al. [1] published their study results. In 
October 2007 Medtronic Inc. issued Urgent Medi-
cal Device Information [2] to all physicians and 
hospitals who were using SF leads stating that 
“no more SF leads will be sold or manufactured 
and any remaining product should be pulled from 
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inventory and returned to the company”. Since 
then, a number of publications have reported 
a variety of risk factors which may be associated with 
Fidelis lead fracture. Polish group of experts lead 
by prof. Adnrzej Kutarski, MD, PhD published in 
2011 in ‘Kardiologia Polska’ journal guidelines for 
management of patients implanted with SF leads [3]. 
This document emphasized the importance of 
consecutive (once every 3 months) control visits 
to centers of cardiac implantable electronic devices 
control. According to this document a malfunction-
ing lead should be replaced with no hesitation. 
The guidelines also advised prophylactic (elec-
tive) replacement of well-functioning lead in three 
situations: (1) after diagnosing pacing dependency 
(idiopathic rhythm < 30/min, asystole > 6 s); 
(2) when estimated lifespan is longer than 10 years; 
(3) on patient’s explicit request after understanding 
the risks and benefits of the extraction procedure. 
Proper identification of each patient’s risk factors 
and well-managed regular control visits are key to 
perpetuate proper functioning of implanted devices 
and reduce the risk of sudden cardiac death, if 
a lead defect has been identified [4]. 
The decision to publish experiences with SF 
leads has been undertaken for the following three 
reasons: (1) to provide information about failure 
rate of 6948 and 6949 SF leads in a single center, 
(2) redefine and assess the importance of risks 
factors according to a population implanted in the 
studied hospital, and (3) make findings available 
for informed management of patients with mal-
functioning leads.
Methods
Patients follow-up
We enrolled all the patients implanted with 
SF leads at First Chair and Department of Cardiol-
ogy, Medical University of Warsaw, Poland. The 
follow-up visits were initially planned according 
to manufacturer guidelines annually at this Outpa-
tient Clinic.  When Medtronic Inc. (Minneapolis, 
Minnesota, USA) published a report on increased 
risk of lead failure [2] an interrogation interval 
had been scheduled for 3–6 months (according 
to patient status severity). In accordance with 
guidelines issued by Kutarski et al. [3], patients 
were recalled  to the preferred contact scheme. 
When the preferred contact scheme had failed in 
establishing any communication with the patient 
or a relative, a registered letter had been sent to 
the last known postal address. After collecting the 
data for the entire group, we  received information 
on the status of each person implanted with SF 
lead (living/deceased and date of death) from the 
PESEL Database (Universal Electronic System for 
Registration of the Population) managed at the time 
of the research by the Ministry of Administration 
and Digitization of Poland. We had also obtained 
information on each patient’s status before im-
plantation from three sources: IMPULS System 
provided by Institute of Medical Technology and 
Equipment, Zabrze, Poland used for registration 
of patients with cardiac implantable electronic 
devices (CIED), where patient’s data is stored by 
the clinic’s staff members, protocols from proce-
dures and data from the hospital discharge cards. 
Clinical and device information gathering results 
were obtained from our ICD database. Additional 
data was retrieved from clinical records. General 
demographic data was also collected.
We acknowledged any death that can be as-
sessed as lead-dependent and every sudden cardiac 
death was reported by the PESEL system. Deaths 
were described as cardiac, non-cardiac and un-
known, according to their cause [5], and the status 
of “sudden” was attributed, provided the death 
occurred in less than 1 h from the beginning of 
symptom presentation [6].
Lead failure was diagnosed when one or more 
of the well established criteria [6–9] were fulfilled: 
(i) a sudden rise in long-term pacing or high-
voltage impedance, (ii) electrical noise artefacts 
as manifested by non-physiological signals on the 
electrogram or by device diagnostics (e.g. non-
physiological short intervals and/or recurrent non-
sustained ventricular tachycardia with intervals 
usually < 220 ms), (iii) failure to sense R-waves 
or ineffective electrical therapy due to an apparent 
structural lead defect. 
Each patient obtained comprehensive and 
detailed information about the elevated risk of 
lead fracture, as well as  the risks of transvenous 
lead extraction procedure. All procedures were 
performed by an electrophysiologist trained in lead 
extraction in a hybrid cardiosurgical operating room 
with a cardiac surgeon on stand-by. 
The study assessed patients’ survivability, lead 
failure and associated symptoms. It also described 
actions in case of an electrode dysfunction. In refer-
ence to the leads, the procedure in each case was 
in accordance with Polish guidelines.
Statistical analysis
Categorical variables were presented as abso-
lute numbers and percentages. Quantitative vari-
ables were expressed as means (standard deviation 
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[SD]) and interquartile ranges (IQR). Categorical 
variables were compared using the Fisher test or 
c2 test. Student t test was used to compare con-
tinuous variables. Kaplan-Meier analysis was 
performed to assess survival free from lead failure. 
Cox regression model was used to establish mortal-
ity predictors. Statistical analyses were performed 
using Statistica software. P value < 0.05 was con-
sidered statistically significant. 
Results
Baseline
Thirty-six SF leads (17 model 6948, 19 model 
6949) were implanted in 36 patients. Baseline pa-
tient characteristics is shown in Table 1. Median 
follow-up time was 76 months (IQR 40.3–86.8). 
The mean left ventricular ejection fraction (LVEF) 
was 34.6% ± 13.0 and only 4 patients had LVEF 
higher than 50%. ICD-DR were implanted in half of 
the patients, ICD-VR in 47.2% and only 2.8% were 
CRT-D. During follow-up the battery was replaced 
in 18 (50%) patients. 
Patients were implanted at median age of 
66.5 years (IQR 57.3 and 72) and majority of 
them had etiology of ischemic cardiomyopathy 
(72% vs. 19% of dilated cardiomyopathy, 3% of 
hypertrophic cardiomyopathy and 6% classified as 
other). Other etiology included long QT syndrome 
(3%) and myocarditis (3%). Leads were implanted 
predominantly through the left cephalic vein access 
(63.9%). Among the studied group, all patients re-
ceived dual-coil leads, 17 (47%) patients received 
a 6948 model SF lead (a passive fixation model), 
and 19 (53%) a 6949 (an active fixation model). All 
ICDs were implanted in the prepectoral area. Lead 
integrity alert was activated in 12 (33%) patients. 
CareLink system was not used (Table 1).
Lead failure
A total of 5 lead failures occurred in this co-
hort. The cumulative overall failure rate for SF 
leads in our center reached 13.9%, with 23.5% for 
the 6948 model, and 5.3% for the 6949, p = 0.12. 
In the group of patients with SF lead failure, the 
following malfunctions occured: electric noise in 
3 patients, and inappropriate shock secondary to 
electric noise in 2 patients, the low ventricular 
sensing in 2 patients. We noted ICD interventions 
(antitachycardia pacing) and shocks in both groups. 
Overall rate of ICD shocks was 68 (53 in failed 
SF group and 15 in the non-failed SF group) with 
15 interventions lacking preceding arrhythmic events 
(2 in patients with non-failed leads). ICD interven-
tions in the form of antitachycardia pacing were 
more common in failed-SF group with 148 (of 156 
in both group). No significant difference has been 
observed in the characteristics of patients receiv-
ing ICD in primary vs. secondary prevention in re-
ceived therapies. Median time from implantation to 
detection of the lead fracture was 52 months (IQR 
49; 83). Lead failure was diagnozed after  45, 49, 52, 
66 and 100 months, respectively after implantation 
in subsequent patients. Lead failure was detected 
after ICD replacement due to elective replacement 
indicator in 2 patients (0 and 12 months after the 
replacement procedure, respectively). 80% of the 
patients with lead failure underwent a procedure 
of ICD replacement due to elective replacement 
indicator. The 1-year, 3-year, 5-year and 7-year lead 
failure was 0%, 0%, 9%, 33%, respectively (Fig. 1). 
Table 1. Patient characteristics
Parameter Overall
Follow-up [years], median, IQR 6.3 (3.4–7.2) 
Age at implantation [years] 66 ± 11.9
Men 26 (72.2%)
Women 10 (27.8%)
LVEF [%], mean ± SD 34.6 ± 13.0 
Etiology: ischemic heart disease 26 (72.2)
Hypertrophic cardiomyopathy 1 (2.8%)
Dilated cardiomyopathy 3 (8.3%)
Other 1 (2.8%)
Primary prevention 28 (77.8%)
Secondary prevention 8 (22.2%)
Access vein: 
Cephalic 23 (63.9%)
Subclavian 13 (36.1)
Type of device: 
ICD-VR 17 (47.2%)
ICD-DR 18 (50%)
CRT-D 1 (2.8%)
Lead tip position: 
Right ventricular outflow track 11 (30.6%)
Apex 24 (66.7%)
Other 1 (2.8%)
Fixation mode:
Active 19 (52.8%)
Passive 17 (47.2%)
IQR — interquartile range; ICD-DR — dual-chamber implantable 
cardioverter defibrillator; ICD-VR — single-chamber implantable 
cardioverter defibrillator; CRT-D — implanted cardiac resynchroni-
zation defibrillator; IQR — interquartile range; LVEF — left ventricu-
lar ejection fraction; SD — standard deviation
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In Figure 1 we present Kaplan-Meier curves for 
survival without SF lead failure. The rise of SF lead 
failure is not associated with the loss of patients 
from the non-diagnosed group (either deceased or 
lost to follow-up) in the 7-year follow-up. In this 
population, patients with dysfunctional lead had 
lower LVEF (median 26% vs. 33%, p = 0.34).
Lead management strategies
Leads were extracted in 6 patients. Four of 
them were extracted after failure diagnosis. One 
patient after receiving a complete information on 
the elevated risk of SF lead failure made a decision 
about elective replacement, no signs of ICD or lead 
dysfunction were present. In 1 patient SF lead was 
extracted because of infective endocarditis. No 
signs of lead failure were present. No complications 
were observed during transvenous lead extraction 
procedures.
Mortality
During the follow-up 15 (42%) patients died 
after a median time from implantation of 38 months 
(IQR 11.5–69.0). Kaplan-Meier survival probability 
curves in subgroups of patients with SF lead are 
presented in Figure 2. Among this group no death 
can be objectively attributed to an ICD lead failure. 
In non-survivor groups there were trends towards 
more frequent implantation in secondary preven-
tion in (93%, n = 14; vs. 12, p = 0.065) and older 
patients (median 69.0 years old [IQR 63; 76] vs. 
66.5 [IQR 57.0; 71.0]; p = 0.09) than in survivors.
Discussion
This single-center research provides im-
portant data on SF lead recipient outcomes. In 
particular, we found comparable to other studies’ 
failure rates during long-term follow-up. The 
cumulative overall failure rate for SF leads in our 
center reached 13.9%, with 23.5% for 6948 model, 
and 5.3% for 6949 model. Failure rate for only 
6948 model was higher than those reported by 
Medtronic Inc. with the active fixation model rate 
lower than this provided by the CareLINK Plus 
(at 8 year survival 7.3% and 16%, respectively) 
[10, 11]. Moreover, it was  observed that due to 
application of the management guidelines fractured 
SF leads probably did not significantly affect pa-
tients’ survival during long-term follow-up.
Figure 1. Survival probability in groups with and without the diagnosis of Sprint Fidelis (SF) lead failure.
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Lead failure
Several studies reported elevated lead failure 
rate of SF leads during long-term follow-up. Most 
of them presented active fixation lead failure rate 
which was 9.1–16.4% in the 5-year follow-up 
[7, 12, 13]. By contrast, passive fixation lead failure 
ranges from 4.2% to 14.4% in the 5-year observa-
tion [6, 7, 10, 14].
In present analysis lead failure rate was 9% at 
5 years, which is a relatively low value compared with 
other literature [6, 7, 12, 15, 16].  A relatively low 
lead failure rate was achieved with implantations 
which involved only double-coil lead in all patients. 
Tzogias et al. [17] presented similar 9.7% failure 
rate in 971 patients with 6949 lead (double-coil) in 
a 5-year follow-up. Piot et al. [15] found that single-
coil lead had over 3-times higher risk of fracture 
compared with double-coil lead. Non-cephalic 
access was used in less than 40% of the studied 
population and ICDs were implanted prepectorally 
in all patients. Both of these factors are claimed to 
be proteting from lead failure [7, 15, 18]. 
During the subpectoral ICD implantation acute 
bend of the lead is seen often. Moreover, lead might 
be damaged because of the constantly repeated 
contraction of the pectoralis muscle [18]. It is not 
clear why non-cephalic access increases the risk of 
lead failure. There is a possibility that cephalic ac-
cess might decrease the hazard of subclavian crush 
syndrome. Recent reports by Krahn et al. [19] also 
showed that ICD replacement cannot be attributed 
to a higher SF lead failure rate This supports the 
presented findings. 
It is known that the lead is the most vulner-
able element of ICD system. Therefore, all  ac-
tions which decrease the risk of lead failure rate 
should be taken, including cephalic access during 
implantation. As survival of the patients with ICD 
and pacemakers increases, so does the risk of 
complications. Alternative therapies are needed. 
One of them is subcutaneous ICD, where the lead 
is located outside of the cardiovascular system [20]. 
However, the lead is still present in this therapy 
and it may also have typical lead complications. It 
follows that lead complications could be avoided 
only after implementation of various techniques. 
Fusion of subcutaneous impulse generator and 
wireless pacemaker would avert the risk of lead 
failure. 
Due to rising interest in establishing predictors 
of higher risk  lead damage [7], it has presently been 
taken into consideration, gathered demographic 
and clinical data in order to reveal whether trends 
were observed elsewhere which may apply to our 
population of patients was considered as well. This 
study has not confirmed previous findings [21–24] 
that patients with confirmed SF lead fracture have 
statistically significantly higher LVEF, the results 
obtained herein present contrary results — in our 
population patients with dysfunctional lead had 
lower LVEF. Additionally, no statistically significant 
correlation has been found according to gender 
Figure 2. Survival probability in subgroups of patients with implanted Sprint Fidelis (SF) lead.
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[7, 9, 12, 25] or age at implantation [23]. Neither 
was any statistical correlation found between the 
type of prevention (primary vs. secondary), venous 
access [7, 18, 21, 24, 26, 27] (cephalic vs. other), nor 
position of the lead tip in the right ventricle (apex 
vs. right ventricular outflow track). All parameters 
were analyzed and were found to be insignificant 
in multivariate analysis, as well in a univariate 
analysis.
Management
Data presented could potentially help physi-
cians implement recommendations with regard 
to recalled leads. Management of patients with 
SF lead involves several steps which are recom-
mended. First, outpatient clinic visits are advised to 
be scheduled more frequently, optimally at 3-month 
intervals. Second, during information gathering 
physicians are well advised to look for any signs of 
lead malfunction. In such cases, the lead could be 
extracted and a new lead  implanted. Third, each 
patient should be comprehensively informed about 
the risks associated with the SF lead. Decisions 
about specific management should be discussed 
with each patient individually. No incidence was 
observed where influence of fractured failure lead 
influenced mortality. Advisory guidelines were ap-
plied which might be regarded as contrary to the 
prophylactic extraction of normally functioning SF 
lead. A position, first presented in Polish guidelines 
regarding SF lead management [3] was recently 
supported by Salgado et al. [28] who reported that 
in a number of Spanish centers preventive SF had 
no superior outcome compared to observation and 
replacement scheduled during generator exchange. 
This study confirms that the SF lead expert rec-
ommendations could be implemented safely and 
effectively.
Mortality
No single death could be categorized as asso-
ciated with lead defect, which concurs with other 
studies [7, 8, 23, 24, 29]. In the literature, there 
are slightly lower mortality rates in SF recipients 
[6]. The trends of this study  show quite the same 
results as in the literature — in non-survivor 
groups, more frequent implantation was in second-
ary prevention [9, 23] and in older ages [9] than 
in survivors. ICD interventions without preced-
ing arrhythmic event also do not worsen clinical 
state of the patients just as Mehta et al. [29] has 
reported. Up to the time of this report, in United 
States, Medtronic Inc. associated 13 deaths with 
SF failure [30].
Limitations of the study
There are several limitations of the present 
study. First, the research was based on retrospec-
tive analysis of prospectively collected data of 
limited, single-center cohort. Second, we do not 
have information on the returned SF leads. Third, 
causes of death could not be verified post mortem 
and therefore lead failure rate might be underes-
timated. 
Conclusions
This study presents the follow-up of patients 
with recalled SF leads in a single center cohort, 
which supports the position that implementation of 
SF management guidelines lead could be effective 
in clinical practice. The failure rate was 13.89% 
which is similar to data reported in other cohorts.
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